I've been reporting on this space in my #Trends report since March 2024two years ago (Navigating Obesity Care in the Digital Age)
Research has suggested BPC-157 may counteract effects of both L-NAME (NO synthase inhibition) and L-arginine (NO substrate overload) behaving as a *balancer* of NO signalling rather than a one-directional agonist or antagonist
Leslie Baumann says in her great Cosmetic Dermatology book that thanks to the unique molecular characteristic of Sodium Cocoyl Isethionate, it "has defined a new dimension in the mildness of cleansing bars "
If you are pregnant: Foundayo should not be used during pregnancy
When analyzed by individual agents, liraglutide demonstrated the strongest protective association (OR = 0.13, 95% CI: 0.050.32, p = 0.0001), followed by dulaglutide (OR = 0.26, 95% CI: 0.11-0.60, p = 0.01) and semaglutide (OR = 0.27, 95% CI: 0.080.98, p = 0.046), all of which were statistically significant